We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Florida Firm for cGMP Violations, Reporting Problems
FDA Warns Florida Firm for cGMP Violations, Reporting Problems
January 3, 2006
The FDA has issued a warning letter to Nephron Pharmaceuticals for allegedly failing to comply with current good manufacturing practices (cGMPs) and postmarketing adverse drug experience (PADE) reporting requirements.